Publication | Closed Access

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

Survival EndpointsSurgical OncologyUrologyGenitourinary CancerMedicinePerioperative Dose-dense MethotrexateMuscle-invasive Bladder CancerCancer TreatmentOncologyRadiation Oncology